Oncology · NSCLCTrial Updateclinicalmid-term

Janssen's Amivantamab Study in Advanced NSCLC Evaluates Safety and Efficacy

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen35 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:30:43 PM

Assessment confidence: 72% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing trial of Amivantamab in advanced NSCLC is critical as it could redefine treatment standards if it shows superior safety and efficacy. Positive results may significantly enhance Janssen's competitive positioning in the oncology market. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 8 ranked evidence items (5 high-relevance).

Strategic Assessment

Positive outcomes could enhance Janssen's portfolio in oncology and provide a competitive edge in the NSCLC market. The strongest clinical anchor is Study of Amivantamab, Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (ClinicalTrials.gov), sub-indication match (lung cancer); entity match (janssen). In lung cancer, 1 regulatory and 4 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sub-indication match (lung cancer); sponsor/company relevance (pfizer). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Patient population match (advanced). The trial results will influence the regulatory pathway for Amivantamab, impacting its approval timeline and labeling in the oncology space.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful outcomes could lead to increased market share for Janssen in the NSCLC segment, potentially translating into substantial revenue growth.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Positive outcomes could enhance Janssen's portfolio in oncology and provide a competitive edge in the NSCLC market.

What Would Change This Assessment

This becomes more urgent if Monitor results for safety and efficacy, as well as the determination of recommended Phase 2 doses for monotherapy and combination therapies.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Patient population match (advanced)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAlow relevance
Regulatory pathway relevance (nda); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Study of Amivantamab, Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (janssen)
FDA document
View source
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With PD-L1 Expression < 1% or
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.govlow relevance
Sponsor/company relevance (Roche)
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: Phase 3 Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedmedium relevance
Patient population match (advanced)
FDA document
View source
Comparative efficacy, recovery, and pigmentary safety of radiofrequency microneedling and fractional carbon dioxide laser for facial atrophic acne scars: a prospective randomized split-face trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
Amivantamab
lazertinib

Commercial impact

high

Successful outcomes could lead to increased market share for Janssen in the NSCLC segment, potentially translating into substantial revenue growth.

Regulatory impact

medium

The trial results will influence the regulatory pathway for Amivantamab, impacting its approval timeline and labeling in the oncology space.

What to watch

Monitor results for safety and efficacy, as well as the determination of recommended Phase 2 doses for monotherapy and combination therapies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.